| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.33 | 5e-11 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.24 | 6e-10 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.28 | 1e-08 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-07 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-07 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-07 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-07 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.25 | 3e-06 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.18 | 9e-06 |